WO2013008253A3 - Imatinib formulations - Google Patents
Imatinib formulations Download PDFInfo
- Publication number
- WO2013008253A3 WO2013008253A3 PCT/IN2012/000488 IN2012000488W WO2013008253A3 WO 2013008253 A3 WO2013008253 A3 WO 2013008253A3 IN 2012000488 W IN2012000488 W IN 2012000488W WO 2013008253 A3 WO2013008253 A3 WO 2013008253A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- imatinib
- salts
- pharmaceutical formulations
- formulations
- relate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Aspects of the present application relate to pharmaceutical formulations comprising imatinib or its salts, isomers, racemates, enantiomers, hydrates, solvates, metabolites, and polymorphs, and mixtures thereof. Further aspects relate to processes for preparing pharmaceutical formulations comprising imatinib or its salts, together with at least one pharmaceutically acceptable excipient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1009CHN2014 IN2014CN01009A (en) | 2011-07-11 | 2012-07-11 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161506191P | 2011-07-11 | 2011-07-11 | |
US61/506,191 | 2011-07-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013008253A2 WO2013008253A2 (en) | 2013-01-17 |
WO2013008253A3 true WO2013008253A3 (en) | 2013-03-07 |
Family
ID=47506639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2012/000488 WO2013008253A2 (en) | 2011-07-11 | 2012-07-11 | Imatinib formulations |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013008253A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201304699D0 (en) * | 2013-03-15 | 2013-05-01 | Remedica Ltd | Pharmaceutical compositions |
ES2683361T3 (en) * | 2013-05-14 | 2018-09-26 | Hetero Research Foundation | Imatinib compositions |
EP3592338A1 (en) * | 2017-03-08 | 2020-01-15 | ARIAD Pharmaceuticals, Inc. | Pharmaceutical formulations comprising 5-chloro-n4 |
MX2022000418A (en) * | 2019-07-15 | 2022-02-10 | Intas Pharmaceuticals Ltd | Pharmaceutical composition of imatinib. |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006121941A2 (en) * | 2005-05-10 | 2006-11-16 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
WO2006133046A2 (en) * | 2005-06-03 | 2006-12-14 | Elan Pharma International, Limited | Nanoparticulate imatinib mesylate formulations |
WO2008027600A2 (en) * | 2006-09-01 | 2008-03-06 | Teva Pharmaceutical Industries Ltd. | Imatinib compositions |
-
2012
- 2012-07-11 WO PCT/IN2012/000488 patent/WO2013008253A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006121941A2 (en) * | 2005-05-10 | 2006-11-16 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
WO2006133046A2 (en) * | 2005-06-03 | 2006-12-14 | Elan Pharma International, Limited | Nanoparticulate imatinib mesylate formulations |
WO2008027600A2 (en) * | 2006-09-01 | 2008-03-06 | Teva Pharmaceutical Industries Ltd. | Imatinib compositions |
Non-Patent Citations (2)
Title |
---|
NONYMOUSLY, D.: "Stable Tablet Formulation containing more than 80% of Imatinib mesylate", IP.COM, 19 February 2008 (2008-02-19) * |
VASANTHAVADA, M. ET AL.: "Application of Melt Granulation Technology Using Twin-screw Extruder in Development of High-dose Modified-release Tablet Formulation", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 100, no. 5, May 2011 (2011-05-01), pages 1923 - 1934 * |
Also Published As
Publication number | Publication date |
---|---|
WO2013008253A2 (en) | 2013-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013098833A3 (en) | Processes and intermediates for preparing rivaroxaban | |
WO2012103226A3 (en) | Bendamustine formulations | |
TW201613567A (en) | Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament | |
WO2016079751A3 (en) | A process for preparation of vortioxetine and polymorphs thereof | |
CR20150114A (en) | COVERED PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB | |
WO2014041565A3 (en) | Improved process for preparation of vilanterol and intermediates thereof | |
WO2014045162A8 (en) | ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS | |
WO2012025944A3 (en) | Sitagliptin, salts and polymorphs thereof | |
PH12015500376A1 (en) | Novel bicyclic pyridinones | |
IN2015DN00845A (en) | ||
WO2014125506A3 (en) | A process for the preparation of ivacaftor and its intermediates | |
HK1206938A1 (en) | Process for the preparation of 3-chloro-4,5,6-trifluoro- picolinonitrile 3--456-- | |
WO2013093931A3 (en) | Novel prodrugs of phenolic drugs | |
PH12015502477A1 (en) | Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione | |
WO2014062838A3 (en) | Pkm2 modulators and methods for their use | |
WO2013008253A3 (en) | Imatinib formulations | |
WO2015002755A3 (en) | Compounds for the treatment of malaria | |
MX351180B (en) | Pharmaceutical composition comprising pyridone derivatives. | |
WO2012018791A3 (en) | Preparation of prasugrel hydrochloride | |
MX2013009386A (en) | New azaspirodecanone compounds. | |
WO2015087343A3 (en) | An improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof | |
PH12015501056A1 (en) | 2-pyridone compound | |
WO2014195977A3 (en) | Novel polymorphs of vismodegib | |
WO2014030173A3 (en) | Improved process for preparation of atazanavir bisulfate | |
WO2013182946A3 (en) | Vilazodone hydrobromide, process for its preparation and vilazodone polymorphs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12810770 Country of ref document: EP Kind code of ref document: A2 |